Archive: June 2012
Case Study Monograph: Community Perspectives: Combining Serology,
Genetics, and Inflammation Markers for the Diagnosis
of IBD and Differentiation Between CD and UC
Douglas C. Wolf, MD, Bincy P. Abraham, MD, MS, Anita Afzali, MD, MPH, Paul D. Allegretti, DO, and Ronen Arai, MD
Diagnosis of inflammatory bowel disease (IBD) is complicated and is based on a combination of patient history and physical examination in association with laboratory, endoscopic, histologic, and radiographic investigations. Determination of the correct diagnosis is important for its implications in selecting treatment and in the timing and type of surgery that may be required. Information from testing incorporating serologic, genetic, and inflammatory markers can help to clarify the clinical picture. Measurement of biomarkers not only helps to differentiate a diagnosis of IBD versus non-IBD, it can also help to distinguish between ulcerative colitis and Crohn’s disease in difficult cases. In this monograph, 5 cases illustrate how specialized testing can provide important information that can aid in diagnosis.
Updates in the Treatment of Hepatitis C Virus Infection From EASL 2012
Jean-Pierre Bronowicki, MD, PhD
Special Reporting on:
• Safety of Telaprevir or Boceprevir in Combination with Peginterferon α/
Ribavirin in Cirrhotic Nonresponders. First Results of the French Early Access Program (ANRS CO20-CUPIC)
• SVR in Prior Peginterferon/Ribavirin (PR) Treatment Failures After
Re-treatment with Boceprevir + PR: The PROVIDE Study Interim Results
• Futility Rules in Telaprevir Combination Treatment
• Boceprevir Plus Peginterferon/Ribavirin for the Treatment of HCV/HIV Co-Infected Patients: End-of-Treatment (Week 48) Interim Results
PLUS Meeting Abstract Summaries